Introduction
Acute lymphoblastic leukemia (ALL) is one of the most common types of leukemia, which represents 75-80% of acute leukemia in children and ~20% of all types of leukemia in adults (1) (2) (3) . The cure rate and 5-year disease free survival (DFS) rate of children patients have markedly improved in previous years (4, 5) . However, the outcomes of adult patients remain poor (6) . The 5-year overall survival (OS) rate of adults of young age (15-39 years old) was demonstrated to be between 42 and 63%. It decreased to 24.1% in those patients between 40 and 59 years old, and to 17.7% in patients between the ages of 60 and 69 (7) . Resistance to chemical drugs is one of the primary factors that leads to treatment failure (8) . Therefore, novel agents with high efficacy rates are required to treat this threating malignancy.
Wee1 encodes a nuclear protein measuring 96 KD, which is a tyrosine kinase belonging to the Ser/Thr family of protein kinases (9) . It is markedly active during S and G2 phase of the cell cycle, and acts as a crucial regulator of the G2/M and DNA damage checkpoints (9) . Cyclin-dependent kinase 1 (CDK1) and cyclin B comprise the maturation promoting factor, which initiates the process of mitosis (10, 11) . Wee1 phosphorylates the amino acids Tyr15 and Thr14 of CDK1, thus inactivating the CDK1-cyclinB complex, arresting cell cycle and preventing mitotic entry (10, 11) . MK-1775 is a selective Wee1 tyrosine kinase inhibitor that inhibits the activity of Wee1 in an adenosine 5'-triphosphate-competitive manner (12) . It induces cell apoptosis by abrogating the G2/M checkpoint in a variety of solid tumors, including: Neuroblastoma (13); Ewing sarcoma (14) ; glioblastoma (15) ; pancreatic (16) , prostate (17) and breast cancer (18) ; hepatic carcinoma (19) ; and acute myeloid leukemia (20, 21) . However, the role of Wee1 in ALL and the potential anti-ALL activity of MK-1775 have not been well elucidated. The present study evaluated the anti-ALL activity of MK-1775 as a single agent and in combination with the cytotoxic drug doxorubicin (Adriamycin ® ; ADM). Potential involvement of the Notch and RAC-alpha serine/threonine-protein kinase (Akt)/mechanistic target of rapamycin (mTOR) signaling pathway during the treatment was also investigated. Statistical analysis. Measurement data are presented as mean ± standard deviation. Differences among ≥ three groups were determined by one-way analysis of variance, followed by Student-Newman-Keuls post-hoc test for multiple comparisons, whereas differences between two groups were evaluated by a Student's t-test. P<0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed using the SPSS 17.0 statistical software (SPSS, Inc., Chicago, IL, USA). Table I ). Then, the effects of MK-1775 on the anti-leukemia effect of ADM on the ALL cells was detected. Nalm-6 (B-ALL) and Jurkat (T-ALL) cells were treated with increased doses of ADM with or without MK-1775 for 48 h. The data indicated that the IC 50 of ADM was decreased with the additional application of MK-1775 compared with single ADM treatment (Fig. 1B) .
Results

MK-1775 inhibits the viability of ALL cells.
MK-1775 promotes cells into G2/M phase.
To determine the effect of MK-1775 on the cell cycle progression of ALL cells in vitro, Nalm-6 and Jurkat cells were cultured in 6-well plates with 0, 100 or 300 nM MK-1775 for 24 h. Cells were collected and stained with PI. Cell cycle analysis was performed with an FCM assay. As indicated in Fig. 2 , compared with the control group, treatment with 300 nM MK-1775 decreased the proportion of Jurkat cells in G1 phase, and more cells were arrested at G2/M phase (P<0.05). The proportion of each phase of Nalm-6 cells treated with 100 or 300 nM MK-1775 did not change significantly compared with the control group (P>0.05).
MK-1775 induces apoptosis of ALL cells.
To determine the effect of MK-1775 induced apoptosis in ALL cells, Nalm-6 and Jurkat were cultured with MK-1775 (0, 100 or 300 nM) for 48 h, then Annexin V-FITC/PI dual staining followed by flow cytometric analysis was performed. The proportion of apoptotic Nalm-6 cells was 3.46±2.25, 64.82±18.44 and 88.83±7.65% respectively, and the proportion of apoptotic Jurkat cells was 2.12±0.47, 41.26±12.30 and 70.08±8.52%, respectively (Fig. 3) .
Then, the synergistic effect of MK-1775 and ADM was detected. Nalm-6 and Jurkat cells were treated with control, 0.05 mg/ml ADM, MK-1775 100 nM, or the combination for 24 h, and apoptosis analysis was performed with flow cytometry. The apoptotic rate of the Nalm-6 cells in the control, ADM, MK-1775 and combination groups was 2.30±1.13, 12.8±5.07, 17.15±7.89 and 49.42±6.82% respectively; the apoptotic rate of the Jurkat cells was 3.01±1.31, 18.50±7.67, 23.25±10.87 and 67.16±7.67%, respectively. MK-1775 combined with ADM induced higher apoptotic rates compared with each single agent and the control in the Nalm-6 and Jurkat cell lines (P<0.05; Fig. 3 ).
MK-1775 induces apoptosis due to unscheduled mitotic entry and downregulation of Notch pathway.
To determine the underlying molecular mechanism of the apoptosis induced by MK-1775, Nalm-6 and Jurkat cells were treated with 0.05 mg/ml ADM, 300 nM MK-1775, or the combination for 24 h, then western blotting was performed to detect the expression of the associated proteins. As demonstrated in Fig. 4 , MK-1775 and ADM increased the expression of H2A histone family, member X (γ-H2AX) and promoted the cleavage of PARP1, which indicated breakage of DNA strand and apoptosis of ALL cells. Additional analysis revealed that MK-1775 treatment suppressed the phosphorylation of CDK1 at Tyr15 and increased the expression of p-H3 (Ser10), which is an index of mitotic entry (23) . It indicated that apoptosis of ALL cells induced by MK-1775 was due to abrogation of G2/M checkpoint and unscheduled mitosis entry. Different from MK-1775, ADM treatment increased the phosphorylation of CDK1 and decreased the expression of p-H3, which indicated that mitotic entry in the cells was inhibited. In addition, the data indicated that the combination of ADM and MK-1775 induced increased γ-H2AX levels and more cleaved PARP1 compared with treatment with ADM alone (P<0.05), which suggests that MK-1775 may enhance the efficacy of ADM in the treatment of ALL. Next, the potential signaling pathway involved in the apoptosis induced by MK-1775 treatment was detected. The results indicated that Notch1 ICN and Notch3 ICN levels were downregulated by MK-1775 (P<0.05), but that the mTOR pathway was not changed (P>0.05; Fig. 4) . However, ADM treatment did not affect the Notch or mTOR pathways as significantly (P>0.05). The relative protein expression was calculated as the density ratio of the protein to be detected to actin.
Discussion
The DNA repairing pathway serves a critical role in the survival of cancer cells (24) . The majority of traditional anti-leukemia chemicals are DNA damaging agents, including antimetabolites, alkylating agents and topoisomerase inhibitors (25) . Tumor protein 53 (p53) serves as a key regulator of G1/S checkpoint (26) . It blocks the initiation of S-phase and activates DNA repairing proteins when DNA has sustained damage (27) . However, p53 was mutated in a variety of types of cancer; consequently, there is dysfunction in the G1/S checkpoint and cells with DNA lesions can enter S phase without DNA repair. In these cancer cells, DNA repair relies on the G2/M rather than the G1/S checkpoint (28) .
Wee1 is a crucial cell cycle checkpoint kinase of G2/M that regulates cell cycle progression and maintains chromatin integrity (29) . In addition, Wee1 serves a critical role in regulating histone synthesis and spindle formation (30) . It phosphorylates the amino acids Tyr37 of H 2 B to terminate the synthesis of histone to maintain the proper histone/DNA stoichiometry before mitotic entry. Wee1 inhibition may force cells in S phase directly into mitosis without completing DNA synthesis, resulting in highly abnormal mitoses characterized by dispersed chromosomes and disorganized bipolar spindles, ultimately resulting in mitotic exit with gross micronuclei formation and apoptosis (31) (32) (33) . MK-1775 is a selective Wee1 kinase inhibitor that has demonstrated a high rate of anti-tumor activity in a variety of types of cancer.
The data of the present study indicated that the B-ALL and T-ALL cell lines were sensitive to the treatment of Wee1 inhibitor MK-1775 in vitro. It inhibited cell viability and induced apoptosis in a concentration-and time-dependent manner. MK-1775 treatment suppressed the phosphorylation of CDK1 and increased the expression levels of p-H3, which is an indicator of mitotic entry (23) . Increased expression levels of γ-H2AX suggested that the unscheduled mitotic entry induced by MK-1775 led to more extensive DNA lesions. PARP is a crucial enzyme responsible for the repair of single-strand DNA breaks (34) . It is cleaved by caspase during the process of apoptosis, and consequently becomes inactive (35) . The data of the present study indicated that MK-1775 treatment led to DNA repair suppression and apoptosis of ALL cells, characterized by cleavage of PARP1. ADM is a common agent applied in the treatment of ALL that destroys DNA structure and inhibits the replication of DNA (36) . The results of the present study indicated that the combination of ADM and MK-1775 led to increased levels of DNA damage compared with each single agent, and as a result induced and increased level of apoptosis. MK-1775 treatment decreased the IC 50 of ADM in the Jurkat and Nalm-6 cells, indicating that it may increase the sensitivity of ALL cells to ADM treatment. In addition, the present study demonstrated that the IC 50 of MK-1775 in the HS-5 cell line was increased compared with all ALL cell types. It indicates that the hematopoietic supportive capacity of bone marrow stromal cells may be reserved during the treatment of MK-1775. It also agrees with the conclusion that MK-1775 is a well-tolerated agent with high safety (37) . In addition, it was identified that MK-1775 exhibited an anti-ALL effect not only in cells with p53 mutations (Jurkat, Sup-T1 and Molt-4), but also in cells with wild type p53 (Nalm-6). A similar result was also identified in sarcomas (38) , which indicates that the status of p53 is not the only predicator of response to the Wee1 inhibitor MK-1775. Other studies revealed that the level of Wee1 expression and CDK1 phosphorylation are also responsible for the efficiency of Wee1 inhibitor in untreated glioblastoma and osteosarcoma (39, 40) . The present study additionally investigated the potential effect of MK-1775 on the Notch pathway, which serves a critical role in the survival of ALL cells (41) . Notch is a conserved transmembrane pathway that consists of 5 ligands [Jagged1, Jagged2, Delta-like ligand (DLL)-1, DLL3, and DLL4] and four receptors (Notch1-4) in mammals (42) . When bound with its corresponding ligands, the Notch ICN is released from the membrane, then translocated into the nucleus and associates with transcription factor Recombination signal binding protein for immunoglobulin Kappa J region, leading to the expression of Notch target genes, for example the HES1/Hes related family BHLH transcription factor with YRPW motif 1 family. A previous study indicated that >50% of T-ALL cases contain activating mutations in the Notch1 gene (43) . Aberrant activation of Notch1 maintains T-ALL cells survival and promotes extra-medullary infiltration (44, 45) . and downregulation of Notch-1 may increase the sensitivity to chemotherapy of co-cultured human T-ALL Jurkat cells (46) . In B-ALL, Notch-3 and Notch-4 signaling may rescue leukemia cells in contact with human bone marrow-derived mesenchymal stromal cells from apoptosis (47) . In addition, Notch has been demonstrated to interact with other signaling pathways in the survival of tumor cells (48, 49) . It may positively regulate the activity of mTOR pathway in T-ALL (50) . Downregulation of Notch-1 may inhibit prostate cancer cell growth and induce apoptosis via inactivation of Akt/mTOR and NF-κB signaling pathways (51) . In the present study, Notch1 and Notch3 were detected to be downregulated by MK-1775 treatment, while the expression and phosphorylation level of mTOR were not altered. This indicates that the anti-ALL activity of MK-1775 was partly mediated by the downregulation of Notch pathway, rather than mTOR. However, additional study is required to identify how the Notch signaling pathway was regulated by Wee1 inhibitor MK-1775.
In conclusion, the results of the present study demonstrated that the Wee1 inhibitor, MK-1775, exhibited significant anti-ALL effects by inducing mitotic catastrophe and downregulation of the Notch pathway. The combination of MK-1775 and cytotoxic agents may be a promising anti-ALL regimen with high efficiency and good tolerance. Additional studies are warranted to examine the safety of this drug in vivo.
